Be Biopharma Stock
HealthTechLooking to sell Be Biopharma stock or options?
Be Biopharma is pioneering B cell medicines designed for applications extending beyond mere cytotoxicity. The company's therapies tackle significant challenges in cell and gene treatments, offering solutions that are durable, reprogrammable, and administrable without harmful conditioning. This innovation empowers healthcare professionals to address diseases such as cancer, autoimmune disorders, and enzyme deficiencies effectively.
Investors Include:
Pathway to Cures, RA Capital Management, Atlas Venture, Alta Partners, Bristol-Myers Squibb, ARCH Venture Partners, DC Investment Partners, Takeda Ventures, Longwood Fund.